Interestingly, the recent TATTON trial demonstrated the promising activity of the MET inhibitor salvolitinib in patients with MET-amplified NSCLC, establishing MET amplification as the most important actionable target after EGFR-TKI resistance besides T790M EGFR mutation [14,15]. This evidence concerns the gene MET and non-small cell lung carcinoma.